Sugi Predict

Sugi Predict / Compounds / SCHEMBL2940780

SCHEMBL2940780

SCHEMBL2940780

CC(C)c1nc2c(Br)c(N)ccc2c(=O)n1-c1ccc(Cl)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TRPV1 Q8NER1 1/20 0.40
▸ HTR6 P50406 1/20 0.38
▸ ESR1 P03372 1/20 0.38
▸ ESR2 Q92731 1/20 0.38
▸ GRM1 Q13255 3/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ KDM4E B2RXH2 1/20 0.36
▸ KCNH2 Q12809 1/20 0.35
▸ HRH3 Q9Y5N1 1/20 0.35
▸ PIK3CD O00329 2/20 0.35
▸ GRM5 P41594 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ DRD1 P21728 1/20 0.34
▸ DRD5 P21918 1/20 0.34
▸ PIK3CB P42338 1/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ CYP2C9 P11712 1/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.34
▸ NPC1 O15118 1/20 0.34
▸ PDE10A Q9Y233 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10446185 0.88 TRPV1 (0.41) TRPV1HTR6ESR1ESR2GRM1
SCHEMBL10446286 0.87 ESR1 (0.44) TRPV1HTR6ESR1ESR2GRM1
SCHEMBL10446308 0.87 TRPV1 (0.43) TRPV1HTR6ESR1ESR2GRM1
SCHEMBL2934618 0.86 TRPV1 (0.40) TRPV1HTR6ESR1ESR2GRM1
SCHEMBL10446303 0.86 TRPV1 (0.40) TRPV1HTR6ESR1ESR2GRM1
SCHEMBL14511597 0.85 TRPV1 (0.39) TRPV1HTR6ESR1ESR2GRM1
SCHEMBL10446193 0.84 TRPV1 (0.38) TRPV1HTR6ESR1ESR2GRM1
SCHEMBL10446311 0.84 SMN1; SMN2 (0.43) TRPV1HTR6ESR1ESR2GRM1
SCHEMBL10446212 0.83 TRPV1 (0.38) TRPV1HTR6ESR1ESR2GRM1
SCHEMBL10446400 0.83 TRPV1 (0.47) TRPV1KDM4EPIK3CDPIK3CBNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9102653-B2 Substituted quinazolinones as vanilloid antagonists NOVARTIS AG (CH) 2015-08-11 — — US disclosed
US-9102653-B2 Substituted quinazolinones as vanilloid antagonists NOVARTIS AG (CH) 2015-08-11 — — US disclosed
US-20140315932-A1 QUINAZOLINONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS NOVARTIS AG (CH) 2014-10-23 — — US disclosed
US-20140315932-A1 QUINAZOLINONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS NOVARTIS AG (CH) 2014-10-23 — — US disclosed
US-8809528-B2 Quinazolinone derivatives useful as vanilloid antagonists NOVARTIS AG (CH) 2014-08-19 — — US disclosed
US-8809528-B2 Quinazolinone derivatives useful as vanilloid antagonists NOVARTIS AG (CH) 2014-08-19 — — US disclosed
US-20120184571-A1 QUINAZOLINONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS NOVARTIS AG 2012-07-19 — — US disclosed
US-20120184571-A1 QUINAZOLINONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS NOVARTIS AG 2012-07-19 — — US disclosed
US-8211902-B2 Quinazolinone derivatives useful as vanilloid antagonists NOVARTIS AG (CH) 2012-07-03 — — US disclosed
US-8211902-B2 Quinazolinone derivatives useful as vanilloid antagonists NOVARTIS AG (CH) 2012-07-03 — — US disclosed
US-7960399-B2 Quinazolinone derivatives useful as vanilloid antagonists NOVARTIS AG (CH) 2011-06-14 — — US disclosed
EP-1978967-B1 QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS NOVARTIS AG (CH) 2010-09-22 — — EP disclosed
US-20080318940-A1 Quinazolinone Derivatives as Vanilloid Antagonists NOVARTIS AG 2008-12-25 — — US disclosed
US-20080318940-A1 Quinazolinone Derivatives as Vanilloid Antagonists NOVARTIS AG 2008-12-25 — — US disclosed
US-20080318940-A1 Quinazolinone Derivatives as Vanilloid Antagonists NOVARTIS AG 2008-12-25 — — US disclosed
CN-101325954-A Quinazolinone derivatives as vanilloid antagonists NOVARTIS AG (CH) 2008-12-17 — — CN disclosed
EP-1978967-A1 QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS Novartis AG (CH) 2008-10-15 — — EP disclosed
US-20080194595-A1 Bone disorders; osteoporosis; analgesics; muscular disorders; inflammatory bowel disorders CITIBANK, N.A., AS NOTES COLLATERAL AGENT 2008-08-14 — — US disclosed
US-20080194595-A1 Bone disorders; osteoporosis; analgesics; muscular disorders; inflammatory bowel disorders CITIBANK, N.A., AS NOTES COLLATERAL AGENT 2008-08-14 — — US disclosed
WO-2007065663-A1 QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS NOVARTIS AG (CH) 2007-06-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194595-A1 Bone disorders; osteoporosis; analgesics; muscular disorders; inflammatory bowel disorders CACNA1A, ALPI, CACNA1E TRPV1 57/4885HTR6 2356/4885ESR1 2832/4885
US-20140315932-A1 QUINAZOLINONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS TRPV1, TRPV3, CACNA1A TRPV1 1/4885HTR6 555/4885ESR1 2643/4885
US-20080318940-A1 Quinazolinone Derivatives as Vanilloid Antagonists TRPV1, TRPV3, TRPV2 TRPV1 1/4885HTR6 199/4885ESR1 2004/4885
US-20120184571-A1 QUINAZOLINONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS TRPV1, TRPV3, TRPV5 TRPV1 1/4885HTR6 642/4885ESR1 2881/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.